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71. Introduction
1.1. Extrahepatic manifestations of HCV
HCV is a world-wide diffused linear, single-stranded RNA virus which
displays both hepatotropism and lymphotropism and may cause hepatic
and extrahepatic manifestations (HCV-EHMs). HCV-EHMs include many
diseases with B-lymphoproliferative and/or autoimmune the most docu-
mented and frequent [1]. The recent availability ofmortality rates in large
cohorts of subjects confirmed the association of HCV infectionwithmany
extrahepatic pathological conditions including cardiovascular, neurologic,
metabolic or renal diseases and extra-hepatic tumors [2–9]. The compar-
ison between patients with persisting HCV infection and those who
cleared the virus, showed that viral eradication significantly reduced the
rate of extra-hepatic deaths [2,5,10,11].
HCV-EHMs can be classified according to the number and strength of
supporting scientific data, as well as the underlying etio-pathogenic
process [12].
The correct approach to patients with HCV-EHMs requires a multi-
disciplinary management. Specialists of different medical areas chal-
lenging with specific HCV-EHMs should take into account the
pathogenetic role of HCV in different underlying pathological processes.This arises the need to define the best criteria to use antivirals and/or
other therapeutic approaches previously standardized for virus-unre-
lated disease variants with comparable pathogenetic process. Interna-
tional, multidisciplinary recommendations for the therapeutic
management of HCV-EHMs in the era of Interferon (IFN)-free anti-
HCV treatment are needed. Therefore, this paper will mainly focus on
the effects of new (IFN-free) and old (IFN-based) anti-HCV treatments
as well as non-viral therapies on the different HCV-EHMs.
Different manifestations, being caused by the same etiologic
agent, often coexist in the same subject. Most of available information
is derived from studies carried out in patients suffering from
cryoglobulinemic vasculitis, CV, the prototype of systemic HCV-EHMs
that will be considered for first. Then, themain organ-specific disorders
(detectable or not in patients with CV) for which enough data are avail-
able will be better detailed, in order to give, for each condition, a picture
based on different and complementary focuses and the most appropri-
ate therapeutic approach.
1.2. Anti-HCV therapy: old and new
The introduction of the first, IFN-based, antiviral therapy (AVT), led
to positive effects on several HCV EHMs, improving survival rates [13–
525A.L. Zignego et al. / Autoimmunity Reviews 16 (2017) 523–54117]. However, this treatment, even in its most effective combination
(Pegylated(Peg)-IFN plus ribavirin (RBV)), had limited efficacy. AVT op-
tions have been recently expanded with the introduction of direct-act-
ing antiviral agents (DAAs), that directly target non-structural
proteins with a key role in HCV replication.
In 2011, the US Food and Drug Administration (FDA) approved the
first generation of HCV NS3 protease inhibitors - also known as “-
previrs”. These molecules block the catalytic site of NS3, preventing
the poly-protein cleavage and thus HCV replication. Currenly approved
“-previrs” include telaprevir and boceprevir (first wave), and
simeprevir, paritaprevir and grazoprevir (second wave).
Two different classes of second wave DAAs have been introduced,
the NS5A and the NS5B inhibitors. The NS5A inhibitors block the stage
of membranous genesis; they are also known as “-asvirs” (daclatasvir,
ledipasvir, ombitasvir, elbasvir, velpatasvir). The NS5B polymerase in-
hibitors or “-buvirs”, include nucleos(t)ide analogs (sofosbuvir) acting
as chain terminators within the polymerase catalytic site, and non-nu-
cleotide inhibitors (dasabuvir), causing conformational changes and
making the polymerase ineffective. The first generation of DAAs needed
the combination of Peg-IFN and RBV and prolonged treatments, while
the currently available therapeutic schedules are based on different
IFN-free (sometimes RBV free) DAA combinations, with shorter therapy
duration (generally 12 to 24weeks),minimal side-effects (Table 1) [18],
and efficacy approaching 100% [18]. The correct choice of these regi-
mens takes into account virus-related features (i.e., HCV genotype/sub-
type) and/or host-related features (i.e., presence/absence of severe liver
disease, low creatinine clearance, drug-drug-interactions). These new
drugs are providing the opportunity for a dramatic change in the anti-
HCV therapeutic approach, eradicating HCV with high efficacy without
IFN related side effects. Main international guidelines are in agreement
on the opportunity to recommend AVT to all HCV infected patients
without a short lifetime expectancy (i.e., http://www.hcvguidelines.
org/full-report-view ). However, universal treatment may not be scaled
up inmany countries for lack of financial resources and/or of health care
infrastructure and indications to prioritization concerning some HCV-
EHMs, essentially based on increased risk of mortality and morbidity
have been defined (http://www.easl.eu/research/our-contributions/
clinical-practice-guidelines/detail/easl-recommendations-on-
treatment-of-hepatitis-c-2016 and http://www.who.int/hiv/pub/
hepatitis/hepatitis-c-guidelines/en/ ; Table 2).Table 1
Main adverse event of second-wave DAAs
Protease inhibitors
Simeprevir
-Photosensitivity
-Contraindicated in cirrhosis (Child-Pugh B or C)
-Hyperbilirubinaemia
Paritaprevir (boosted
with ritonavir)
-Drug-drug interactions (due to ritonavir)
-Contraindicated in cirrhosis (Child-Pugh B or C)
-Hyperbilirubinaemia
-Hypertransaminasemia
Grazoprevir -Well tolerated
NS5A inhibitors
Ledipasvir
-Well tolerated
-Some drug-drug interactions (with acid
suppressants)
Ombitasvir -Well tolerated
Daclatasvir -Well tolerated
Elbasvir -Well tolerated
NS5B inhibitors
Sofosbuvir
-Contraindicated in severe renal impairment
(estimated GFR less than 30 ml/min)
-Some drug-drug interactions (with amiodarone)
Dasabuvir -Well tolerated2. Methods
The production of therapeutic guidelines for HCV-EHMs was con-
ceived and organized by the International Study Group of Extrahepatic
Manifestations Related to Hepatitis C Virus Infection (ISG-EHCV),
which is a multidisciplinary international network of recognized ex-
perts in this field. In order to provide an homogeneous therapeutic ap-
proach to patients with HCV-EHMs, the ISG-EHCV convenor and co-
convenors invited other ISG-EHCV members on the basis of their well-
known expertise in the field of each HCV-related manifestation. This
task force initially gathered via e-mail and successively via teleconfer-
encemeetings for the discussion of different issues. A systematic review
of the literature specifically correlated to the different HCV-EHMs was
done, representing the backbone of the paper [19] .
3. Results: therapeutic approach to the single HCV-EHMs
The first, essential step for a correct therapeutic approach to HCV
EHMs is represented by an accurate general assessment of patients
and diagnosis of single HCV-EHMs, as previously described [19].
The therapeutic approach to the main HCV-EHMs are described in
the following paragraphs by starting with the CV; since the majority
of the studies are focused on patients with CV, this systemic disorder
represents a precious model for the analysis of the effects of etiologic
therapy on HCV EHMs.
3.1. Cryoglobulinemic vasculitis (CV)
CV is the most frequent and largely investigated HCV-EHM [1,12,20,
21]. A detailed and complete description of this complex disease, in its
different aspects, will be the object of a dedicated paper by our study
group (see Saadoun et al., manuscript in preparation). In the present
paper, the essential aspects justifying the most opportune therapeutic
approach will be considered.
CV is a both autoimmune and lymphoproliferative disease (LPD),
clinically benign (although sometimes with a severe presentation),
but possibly evolving into lymphoma [20,22–24]. The pathological sub-
strate of CV is theHCV-driven B-cell lymphoproliferation and the conse-
quent production of cryo- and non-cryoprecipitable immune
complexes, in turn responsible for vasculitic manifestations. Mixed
cryoglobulins (CGs) are immune complexes that reversibly precipitate
when the temperature is lower than 37 °C [12,22,25,26] and that consist
of Ig (usually IgM)with rheumatoid factor (RF) activity [mono- or oligo-
clonal in type II mixed cryoglobulinemia (MC), or polyclonal in type III
MC] and polyclonal IgGs [27]. Most CV patients are HCV positive (70–
90%) and conversely 40–60% of HCV infected patients produce CGs of
whom 5–30% with symptomatic CV [12,22,25,26]. Since HCV infects
about 170 million individuals worldwide, the number of patients at
risk for developing CV is substantial. The syndrome is characterized by
the typical clinical triad - purpura, weakness, and arthralgias, low com-
plement C4 fraction serum level and various visceral organ involve-
ment, including renal, neurological, cardiac or digestive disease.
According to the vasculitis severity, patients maymanifestmild/moder-
ate disease (i.e., purpura, articular involvement, mild sensory neuropa-
thy), severe disease (i.e., extensive/ulcerative skin disease, severe
sensory-motor neuropathy, glomerulonephritis with impaired renal
function, gastrointestinal involvement) or life-threatening conditions
(i.e., rapidly progressive glomerulonephritis, CNS involvement, intesti-
nal ischemia, alveolar hemorrhage).
3.1.1. Etiologic treatment
3.1.1.1. IFN-based AVT. After the first, pioneering studies using recombi-
nant IFNα in 1993 [13,28–30], AVT followed the evolution of hepatitis C
treatment with some differences (i.e., in the drug doses/duration, com-
bination with non-viral therapies) (Table 3), essentially due to the
Table 2
Individual health criteria for prioritization in case of HCV extrahepatic manifestations
EASLa WHOb AASLD/IDSAc
Metabolic syndrome No specific indications Prioritized No specific indications
Cryoglobulinemia vasculitis Prioritized Prioritized No specific indications
Lymphoproliferative disorders Prioritized Prioritized No specific indications
Renal disease Prioritized Prioritized No specific indications
Debilitating fatigue Prioritized Prioritized No specific indications
Significant psychosocial morbidity No specific indications Prioritized No specific indications
a European Association for the Study of the Liver (EASL) Recommendations, 2016; http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommen-
dations-on-treatment-of-hepatitis-c-2016
b WHO: World Health Organization: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/
c AASLD/IDSA: American Association for the Study of Liver Disease (AASLD)/ Infectious Diseases Society of America (IDSA): No specific indications: “Treatment is recommended for all
patients with chronic HCV infection, except those with short life expectancies that cannot be remediated by treating HCV, by transplantation, or by other directed therapy” http://
www.hcvguidelines.org/full-report-view
526 A.L. Zignego et al. / Autoimmunity Reviews 16 (2017) 523–541possible side-effects of IFN and/or RBV therapy (i.e. IFN neurotoxicity
and myelo-inhibitory action and RBV hemolytic effects). The main
steps in IFN-based AVTwere represented by IFNmonotherapy, its com-
bination with RBV, and the combination of pegylated-IFN (PegIFN) and
RBV that represented the standard of care for about fifteen years. The vi-
rological and clinical results progressively improved, but not the type or
rates of side-effects. Clinical remission was clearly correlated with viro-
logical response (sustained virological response (SVR): prolonged neg-
ative viremia), although with some discordant data [31–36], including
the persistence of CV in rare patients with SVR. However, this rare situ-
ation was generally transient or related to severe sequela of CV or the
presence of a B-cell NHL. Possible explanations included the evolution
to a late stage when the B-cell proliferation became independent fromTable 3
Interferon-related treatment of cryoglobulinemic vasculitis
Refer.
no.
Author Year No. patients Treatment
[2] Ferri 1993 26
2 MIU IFN/d (1m) → 2 MIU IFNx3/w
(5m)
[13] Ferri 1993 15
2 MIU IFN/d (1m) → 2 MIU IFNx3/w
(4m)
[29] Marcellin 1993 2 3 MIU IFNx3/w
[30] Johnson 1993 4 1–10 MIU IFN
[235] Zimmermann 1993 1 3 MIU IFNx3/w
[236] Bojic 1994 1
3 MIU IFNx2/w (4w) → 3 MIU
IFNx3/w (2w)
[14] Misiani 1994 27
1.5 MIU IFNx3/w (1w) → 3 MIU
IFNx3/w (23w)
[51] Dammacco 1994
15
17
3 MIU IFNx3/w
3 MIU IFNx3/w
[237] Johnson 1994 8 3 MIU IFNx3/w
[238] Mazzaro 1994 18 (5 NHL) 3 MIU IFNx3/w
[239] Gilli 1996 1 3 MIU hIFN-αx3/w
[240] Harle 1995 1 3 MIU IFNx3/w
[241] Mazzaro 1995
18
18
(8 NHL)
3 MIU IFNx3/w
3 MIU IFNx3/w
[242] Migliaresi 1995 18 3 MIU IFNx3/w
[243] Yamabe 1996 1
10 MIU IFN/d (2 w) → 10 MIU
IFNx3/w (6 w)
[244] Casaril 1996 36 6 MIU IFNx3/w
[245] Cohen 1996 16 3 MIU IFNx3/w
[15] Adinolfi 1997 50 3 MIU IFNx3/w
[246] Sarac 1997 1
3 MIU IFNx3/w (6 m) → 10 MIU IFN/
d (2 w)→ 10 MIU IFNx3/w (6 w)
[247] Zuber 1997 2
Pt. 1: 3 MIU IFNx3/w
Pt. 2: 3 MIU IFNx3/w (3 m) → 6 MIU
IFNx3/w (7 m)→ 3 MIU IFNx2/w
[248] Akriviadis 1997 20 3–5 MIU IFNx3/w
[249] Casato 1997 31 3 MIU IFN/d (3m) → 3 MIU IFNx3/wthe etiologic agent, with persistence of the pathogenetic B-cell clone ex-
pansion and the evolution to overt lymphoma (see Fig. 1). Also, a too ad-
vanced tissue damage could affect a full functional restoration, for
example for a severe sensory-motor peripheral neuropathy. Therefore,
a prompt and early HCV eradication was reputed essential. The com-
plexity of such autoimmune/lymphoproliferative disorder suggested a
sufficiently long follow up after HCV eradication to evaluate its real ef-
fects on CV symptoms. In a prospective and controlled study including
more than 400 HCV infected patients with/without CG and with/with-
out CV, after a mean follow-up of 8 years, all CV symptoms persistently
disappeared in 57% of SVR patients; some signs and/or symptoms
persisted in the remaining patients, although improved. All virological
non-responders were also clinical non-responders, despite of aCS
Treatment
duration
(months)
Virological response Clinical responsec
EOT Sustained EOT Sustained
Yes 6 13% n.a. 1 n.a.
Yes 5 8% n.a. 93% n.a.
n.a. 6 0% n.a. 50% 0%
No 2–12 100% 75% 75% n.a.
No 3 n.a. n.a. Worsening n.a.
No 6 w n.a. n.a. Worsening n.a.
No 6 60% 0% 6/7 0%
No
Yes
12
12
42%
50%
17%
14%
53%
53%
13%
18%
No 6–12 n.a. n.a. 75% n.a.
No 12 44% 22%
28% complete
50% partial
Clinical resp
CGs pos
No 10 1 (100%) 1 (100%) 1 (100%) 1 (100%)
No
2 w
(5
injections)
n.a. n.a. Worsening n.a.
No
No
6
12
44%
50%
11%
22%
28%
39%
11%
22%
No 12 n.a. n.a. 72% 28%
No 2 1 (100%) 1 (100%)
Clinical resp
CGs pos
Clinical resp
CGs pos
No 6 n.a. n.a. 31% 19%
Variable 6 n.a. n.a. 56% 0%
No 12 n.a. n.a. 44% 12%
No 8 1 (100%) 1 (100%) 1 (100%) CGs pos
No
No
2.5
n.a.
1 (100%)
0%
n.a.
n.a.
1 (100%)
(reduced
cryocrit)
0%
n.a.
No 6–12 n.a. n.a. 65% 20%
No N12 n.a. 11/23 55% 29%
Table 3 (continued)
Refer.
no.
Author Year No. patients Treatment CS
Treatment
duration
(months)
Virological response Clinical responsec
EOT Sustained EOT Sustained
(N9m) (48%)
[250] Mazzaro 1997 42 (7 NHL) 3 MIU IFNx3/w No 12 n.a. 14% 31% 14%
[251] Donada 1998
13 Rel
4 NR
6 MIU IFNx3/w (3 m) → 3 MIU
IFNx3/w (3 m) + RBV (6 m)
No 6
85%
0%
38%
0%
n.a.a 38.5%
[252] Durand 1998 5 NR RBV No 10–36 0% 0%
4 improvement
1 stabilization
n.a.
[253] Gordon 1998 1 1.5 MIU IFNx3/w Yes
1 w
(2
injections)
n.a. n.a. Worsening n.a.
[254] Scelsa 1998 2
Pt 1: 3 MIU IFNx3/w (1 m)→
prednisone→ 1 MIU IFNx3/w
Pt. 2: 3 MIU IFNx3/w
Yes
Yes
6
3 injections
n.a. n.a.
Worsening of
polyneuropathy
n.a.
[255] Calleja 1999
18
8 NR
5 Rel
3 MIU IFNx3/w
3 MIU IFNx3/w + RBV
(retreatment)
3 MIU IFNx3/w + RBV
(retreatment)
No
No
No
12
12
12
55%
62%
100%
27%
37.5%
80%
55%
62%
100%
27%
37.5%
80%
[256] Cid 1999 3 3 MIU IFNx3/w Yes 2–4 n.a. n.a.
Worsening of
ischemic lesions
n.a.
[257] Cresta 1999 43 3 MIU IFNx3/w No 6 42% 14% 40% 14%
[258] Friedman 1999 1 3 MIU IFNx3/w No 3 w n.a. n.a. Exitus n.a.
[259] Misiani 1999 1 3 MIU IFNx3/w + RBV (4 m) No 16 100% 100% 100% 100%
[50] Mazzaro 2000 7 (2 NHL) 3 MIU IFNx3/w No 6 29% 14% 14% 14%
[225] Zuckerman 2000 9 3 MIU IFNx3/w + RBV No 6 22% 22% 78% 56%
[260] Garini 2001 2
Pt. 1: 3 MIU IFNx3/w + RBV
Pt. 2: 3 MIU IFNx3/w + RBV
No
6
12
1 (100%)
1 (100%)
1 (100%)
n.a.
1 (100%)
CGs pos
1 (100%)
n.a.
[261] Naarendorp 2001 10 3 MIU IFNx3/w No 3–60 n.a. n.a. n.a.b n.a.b
[262] Beddhu 2002 10
3 MIU IFNx3/w
4 pts.NR retreated with: 10 MIU/d (2
w) → 10 MIUx3/w (6 w)
No
12
2
n.a.
n.a.
10%
25%
10%
50%
10%
50%
[35] Cacoub 2002 14 Variabile IFN + RBV Variable 6–56 n.a. 64% n.a. 10/14
[263] Casato 2002 1
3 MIU IFN/d → 3 MIU IFNx3/w→ 3
MIU IFN/d
No 18 0% 0% Remission n.a.
[264] Loustaud-Ratti 2002 2
Pt. 1: 3 MIU IFNx3/w
3 MIU IFNx3/w + RBV
(retreatment)
Pt. 2: 3 MIU IFNx3/w → plus RBV
No
No
Yes
12
12
12
1 (100%)
1 (100%)
1 (100%)
0%
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
0 %
1 (100%)
1 (100%)
[265] Sikaneta 2002 1 OLT
2 MIU IFNx2/w + RBV→ Peg-
IFN + RBV
Yes 10
n.a. (neg
in
treatment)
-
n.a. (neg in
treatment)
n.a.
[266] Bruchfeld 2003 2
Pt. 1: 3 MIU IFNx3/w + RBV
Pt. 2: Peg-IFN + RBV
Yes
No
6
6
1 (100%)
1 (100%)
0%
1 (100%)
1 (100%)
1 (100%)
vasculitis
flare
1 (100%)
[36] Mazzaro 2003
27 (3NHL)
NR or Rel.
3 MIUx3/w + RBV No 12 5/24 (21%)
5/24
(21%)
15 immunol. resp
19 clinical resp
(transient)
5/24 (21%)
[267] Rossi 2003 3 RBV (4 w) → 3 MIU IFNx3/w + RBV No 13 3 (100%) 3 (100%) 3 (100%) 3 (100%)
[268] Alric 2004 18
3 MIUx3/w + RBV (n = 14) or Peg-
FN + RBV (n = 4)
Variable 6–24 72% 66.6% n.a. n.a.
[269] Batisse 2004 1 Peg-IFN No 1 0% 0% worsening n.a.
[270] Cacoub 2005 9 Peg-IFN 1.5 μg/kg/w + RBV Variable 10–26 89% 78% 100% 88%d–56%e
[271] Levine 2005 4
Pt. 1: Peg-IFN + RBV
Pt. 2: IFN
Pt. 3: Peg-IFN + RBV
Pt. 4: IFNx3/w + RBV
No
No
No
No
6
18
12
12
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
No
CGs increase
CGs increase
CGs pos
n.a.
[272] Mazzaro 2005 18 Peg-IFN 1 μg/kg/w + RBV No 12 83% 44%
89% complete
11% partial
44%
[273] Vigani 2005 1 3 MIU IFNx3/w + RBV No 48 1 (100%) 1 (100%)
MCS resp
CGs pos
n.a.
[274] Saadoun 2006 72 (9 NHL)
3 MIU IFNx3/w + RBV (32 pts)
Peg-IFN + RBV (40 pts)
Variable ≥6
63%
75%
53%
63%
47%d–28%e
73%d–60%e
56%d–31%e
68%d–58%e
[34] Garini 2007 4
Pt. 1: 3 MIU IFNx3/w + RBV
Pt. 2: 3 MIU IFNx3/w + RBV
Pt. 3: Peg-IFN + RBV
Pt. 4: Peg-IFN + RBV
No
No
Prior
No
6
12
12
12
1 (100%)
1 (100%)
1 (100%)
0%
1 (100%)
n.a.
1 (100%)
-
1 (100%)
CGs pos
1 (100%)
Partial resp
1 (100%)
n.a.
1 (100%)
Rel
[33] Montalbano 2007 1 Peg-IFN + RBV No 12 1 (100%) 1 (100%) CGs pos n.a.
[275] Parise 2007 31 3 MIU IFNx3/w + RBV n.a. 6–12 n.a. 29% 32% n.a.
[31] Joshi 2007
38
(treatments=47)
- IFN (8)
- Peg-IFN (5)
- Consensus IFN (2)
- IFN + RBV (18)
- Peg-IFN + RBV (14)
No 6–12 n.a.
25%
0%
50%
17%
71%
n.a.
62.5%
40%
50%
72%
71%
(continued on next page)
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Table 3 (continued)
Refer.
no.
Author Year No. patients Treatment CS
Treatment
duration
(months)
Virological response Clinical responsec
EOT Sustained EOT Sustained
[276] Koziolek 2007 1
(Peg-IFN + RBV→ Peg-IFN) +
cryoprecipitate apheresis
Yes N6 1 (100%) n.a. 1 (100%) n.a.
[277] Trebst 2007 1
Peg-IFN + RBV (14 m)→ Peg-IFN (4
m)
No 18 0% n.a. 100% n.a.
[278] De Blasi 2008 1 Peg-IFN + amantadine No 4 1 (100%) 1 (100%)
CGs increase
MCS symptoms
n.a.
[279] Landau 2008 49 (9 NHL) Peg-IFN + RBV n.a. N6 n.a. 59.2% n.a. 69.4%
[32] Landau 2008 8 (3 NHL) IFN + RBV or Peg-IFN + RBV n.a. 12–25 n.a. 100% 100% 0%
[16] Mazzaro 2011 86 Peg-IFN + RBV n.a. 6–12 72% 50% n.a. 88.5%
[280] Donato 2013 1 OLT
Peg-IFN + RBV (8 m)→ IFN + RBV
(4 m)
Yes 12 1 (100%) 1 (100%) 1 (100%) 1 (100%)
[281] Saadoun 2014 23
Peg-IFN + RBV + BOC (8)
Peg-IFN + RBV + TPV (15)
Variable 12 69.6% n.a. 56.5% n.a.
[282] De Nicola 2014 1 Peg-IFN + RBV + TPV n.a. 12 1 (100%) 1 (100%) 1 (100%) 1 (100%)
[39] Gragnani 2014 22 Peg-IFN + RBV + BOC No 12 n.a. 23.8% n.a. 0%
[40] Stine 2014 3 Peg-IFN + RBV + SOF n.a. 3 100% n.a. n.a. n.a.
[61] Urraro 2015 1 RTX → Peg-IFN + RBV + BOC No 10 1 (100%) 1 (100%) n.a. 1 (100%)
[38] Saadoun 2015 30
Peg-IFN + RBV + BOC (13)
Peg-IFN + RBV + TPV (17)
Variable 12 n.a.
20
(66.7%)
n.a. 66.7%d–33.3%f
[17] Gragnani 2015 121 Peg-IFN + RBV No 6–12 n.a. 52% n.a. 50.4%d
[41] Cornella 2015 5
Pt. 1: Peg-IFN + RBV + BOC
Pt. 2: RTX → Peg-
IFN + RBV + TPV→
PEG-IFN+RBV → PEG-
IFN + RBV + SOF
Pt. 3: Peg-IFN + RBV + TPV
Pt. 4: RTX → Peg-IFN→ Peg-
IFN + RBV
→ Peg-IFN + RBV + SOF
Pt. 5: RTX → Peg-
IFN + RBV + SOF→ RTX
(maintenance regimen for low grade
lymphoma)
No
No
No
Yes
No
7
1 → 3→15
weeks
11
n.a.
3
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
1 (100%)
Partial response
Clearance of CGs
NR
NR
CGs clearance
Partial
response
Clinical NR
NR
NR
CGs clearance
IFN: interferon; Peg-IFN: pegylated-interferon; RBV: ribavirin; BOC: boceprevir; TPV: telaprevir; SOF: sofosbuvir; MIU: millions of international units; d: day; m: months; w: weeks; n.a.:
not available; pt: patient; CS: corticosteroids; EOT: end of treatment; NR: non responder/s; Rel: relapser/s; CGs: cryoglobulins; MCS: Mixed Cryoglobulinemia Syndrome; NHL: Non-
Hodgkin's Lymphoma; immunol: immunological; resp: response; pos: positive; neg: negative.
a Significant reduction of cryocrit values (transient in relapsers and persistent in sustained virological responders).
b Coincidence between sustained virological and clinical response.
c The clinical response was variably classified in different studies: data are only partially comparable.
d Complete clinical response.
e Complete immunological response.
f Partial clinical response.
528 A.L. Zignego et al. / Autoimmunity Reviews 16 (2017) 523–541transient improvement in some cases. Furthermore, the CGwas a nega-
tive prognostic factor of virological response [17]. In consideration of all
available data, the IFN-based AVT was recommended as the first-line
option in mild to moderate CV [37].
The introduction offirst-generationDAAs thatwere associated to Peg-
IFN and RBV increased SVR rates, but also the side-effects. Saadoun et al
described their safety and efficacy in 30CVpatients [38],where 67%of pa-
tientswere complete clinical and virological responderswhile severe side
effects occurred in 47%. Another study confirmed the goodefficacy of such
combination in 22 cryoglobulinemic subjects, with a CG disappearance in
86% but a lower SVR rate in cryoglobulinemic patients than in patients
without mixed cryoglobulinemia (23.8% vs 70%, p= 0.01) [39]. Stine et
al. in small case series of CV patients treated with triple AVT (Peg-IFN
plus RBV plus sofosbuvir or first generation DAAs) suggested a longer
treatment for cirrhotic patients, apparently more refractory to clear CGs
[40,41].
3.1.1.2. Interferon-free AVT (Table 4). Limited, but essentially concordant
data, are available regarding patients with CV. The first study reported
the effects of a sofosbuvir/RBV combination for 24 weeks in 24 CV pa-
tients [42]; SVRwas scored in 74% patients, with high rate of clinical re-
sponse (87%) and low rates of serious adverse events [42]. The rate of
SVR was that expected from used AVT protocols. Sise et al., using
sofosbuvir-based combinations in 12 CV subjects, obtained animprovement in renal function with or without immunosuppressant
and SVR12 in 83% [43]. An interim analysis, mostly based on the combi-
nation of paritaprevir/ritonavir, ombitasvir, plus dasabuvir, showed a
cryocrit decrease and a clinical response even during treatment [44].
The clinical improvement rate gradually increased from the inhibition
of viral replication, end of treatment and SVR12 [45]. A very recent pro-
spective study assessed efficacy and safety of sofosbuvir-based individ-
ually tailored therapy, in a cohort of 44 consecutive CVpatients (median
after treatment follow-up: 42weeks, range 27–53) [46]. All patients ob-
tained viral eradication and an overall 100% rate of clinical (complete or
partial) response at week 24 post-treatment. Interestingly, a progres-
sive increase of complete response rate over time, confirmed previous,
preliminary observations. This is also suggested by another recent
study conducted on 64 patients with circulating CGs (35/64 with CV)
mostly treated in IFN-free regimens [47]. Recently, Hegazy et al. de-
scribed a cohort of Egyptian and Italian CV subjects [48] and Kondili et
al. reported results of a nationwide Italian study, showing the disap-
pearance or improvement of more than 50% of CV symptoms in 31/37
(84%) patients after DAA [49]. Available data suggest that IFN-free AVT
is safe, generally well tolerated and effective in CV patients.
3.1.2. Non-etiologic treatment
The non-etiologic therapy of CV remains useful for severe patients
before and during AVT, and sometimes after AVT for patients with
529A.L. Zignego et al. / Autoimmunity Reviews 16 (2017) 523–541persistent symptoms. However, it is not recommended as maintenance
therapy after complete symptom remission, evenwhen cryocrit, abnor-
mal RF and/or complement levels are still altered.
This approach is usually based on anti-inflammatory drugs [i.e.,
glucocorticosteroids (GCs)], immune-suppressants [i.e., cyclophospha-
mide (CTX)], azathioprine, biological drugs [rituximab (RTX)], and anal-
gesics, including non-steroidal anti-inflammatory drugs (NSAIDs).
Furthermore, low-antigenic diet and apheresis can be helpful to de-
crease serum CGs levels, particularly in case of renal involvement.
These measures should be used considering the potential effects on
viral replication and liver damage; the administration during DAA ther-
apy, requires a mandatory evaluation of the drug-drug interactions.
GCs are commonly used to control inflammation and pain [50–55].
Low-medium doses of GCs (0.1–0.5 mg/kg/day) usually control mild
to moderate symptoms, whereas high-dose pulse therapy (1–
10 mg/kg) is commonly indicated to manage severe and acute condi-
tions, specifically renal failure, neurologic manifestations or hypervis-
cosity syndrome [37,50,51,56]. The risk of multiple side-effects should
be considered in case of GCs long-term administration [51–53,57]. In
particular, in case of severe liver damage, the effects on viral replication,
electrolyte balance (ascitic decompensation) and lipid metabolism
(liver steatosis), have to be evaluated. The prolonged treatment with
GCs, although common in clinical practice, has preferably to be avoided
or at least reduced. Colchicine has been used as steroid-sparing agent to
reduce Ig secretion [58,59]. It could have favorable transient effects on
purpura, weakness, and leg ulcers when administered at dose of
1 mg/day for 6–48months. The use is limited by the risk of gastrointes-
tinal side-effects [58]. The low-antigen-content diet was reputed toFig. 1. Hypothetical pathogenetic process of lymphoproliferative disorders. During HCV ch
progressively lead such lymphoproliferation to lose the dependence from the etiologic viral a
different factors: the HCV ability to infect these cells; the E2-CD81 binding, that lowers the a
cytokines, first of all the B-cell Activating Factor (BAFF). The apoptosis inhibition and the con
t(14;18) translocation leading to overexpression of the anti-apoptotic protein Bcl-2 togeth
particular host genetic pattern, preparing a favorable background for the onset of HCV-relat
pathogenesis. The addition of other unknown genetic aberrations, would lead to a frank mali
lymphoproliferative disorders; E2: HCV E2 protein; BAFF: B-cell Activating Factor; t(14;18): c
2) gene and protein; NHL: non-Hodgkin's lymphoma.restore phagocyte activity and modify the composition of circulating
immune-complexes. Inmild tomoderate CV, this diet was shown to re-
duce symptoms and laboratory signs [37,60]. Although it is still matter
of debate, its use has been proposed as a supportive treatment for all
symptomatic patients [55]. Analgesic drugs and NSAIDS are used to ob-
tain a relief and reduce the GCs administration, especially in patients
with peripheral neuropathy. Acetaminophen, gabapentin or pregabalin,
opioids, and amitriptyline are themost used. The analgesics andNSAIDS
administration is tailored on specific CV symptoms and on liver disease
degree (especially for NSAIDs and benzodiazepines).
Other approaches have been shown to be very effective in severe CV;
among them, Rituximab (monoclonal antibody against the B-cell specif-
ic CD20 antigen) has a prominent role [41,61]. RTX binding to CD20
causes a B-lymphocytes depletion thus justifying the extensive use in
B-lymphoproliferative disorders and severe autoimmune diseases. The
safety and efficacy of RTX monotherapy in CV were clearly shown
[62–81]. RTX is especially recommended in case of HCV related CV
with severe clinical manifestations, preferring it to more conventional
treatments. RTX can improve various manifestations of CV, including
skin symptoms (purpura and ulcers) [62,63,65], fatigue, arthralgias/ar-
thritis, glomerulonephritis (GN) and, peripheral neuropathy in a rele-
vant number of cases (75–90%) [62,63,65–67,75], including some life-
threatening complications such as hyper-viscosity syndrome [37,62–
81] or gastrointestinal vasculitis [69–71]. It has been reported that
RTX is able to restore someCV-related immune abnormalities; it can de-
crease cryocrit, improve RF andC4 levels [82], and induce thedisappear-
ance of bone marrow B cell clonal expansion. Furthermore, RTX has a
steroid-sparing effect [62,66,83]. Most studies used the standardronic infection HCV-related LPDs arise from a cascade of mechanisms and events that
gent (no-return points). The prolonged and abnormal B-cell stimulation is sustained by
ctivation threshold of lymphocytes; a direct action of HCV proteins; the effect of several
sequent prolonged B-cell survival, could be caused by different events, particularly the
er with other genetic mutations. It is conceivable that all these mechanisms work on a
ed LPDs. A contribution of epigenetic modifications could also take part to this complex
gnancy that can progressively become independent from the viral etiologic agent. LPDs:
hromosomal translocation (14;18) or Bcl2 gene rearrangement; Bcl-2 (B-cell lymphoma
Table 4
Interferon-free treatment of cryoglobulinemic vasculitis
Refer.
no.
Author Year
No.
patients
Treatment CS
Treatment duration
(months)
Virological
response
Clinical responsea
EOT Sustained EOT Sustained
[283] Sultanik 2015 1 SOF + RBV until week 4 then SOF + DAC No 3
1
(100%)
1 (100%) n.a. n.a.
[42] Saadoun 2015 24 SOF + RBV No 6 91.7% 74%
87.5% complete
12.5% partial
86.9%
[43] Sise 2016 12 4 SOF + RBV, 8 SOF + SIM No 3–6 100% 83% n.a.
33.3%
complete
33.3% partial
[284] Flemming 2016 1 SOF + LEDIPASVIR + RBV No 3 100% 100% n.a. n.a.
[285] Sollima 2016 7
• Ombitasvir/paritaprevir/ritonavir +
dasabuvir
• SOF + RBV
• SOF + DCL
• SOF + SIM
No 3–6 100% 100% n.a. 14.3%
[46] Gragnani 2016 44
• 18 SOF + RBV
• 12 SOF + SIM (6 + RBV)
• 4 SOF + DCL (1 + RBV)
• 10 SOF + LED (3 + RBV)
No 3–6 100% 100%
25% full
complete
34% complete
25% partial
16% non
responder
35% full
complete
41% complete
24% partial
[47] Bonacci 2016 30
• 10 Ombitasvir/paritaprevir/ritonavir +
dasabuvir
• 10 SOF + LED
• 2 SOF + SIM
• 3 SIM + DCL
• 2 SOF + DCL
• 3 other
n.a.b 3–6 n.a.b n.a.b n.a.b
66.6%
complete
16.7% partial
n.a.: not available
a The clinical response was variably classified in different studies: data are only partially comparable.
b It is not possible to complete this field since the analysis reported in the paper includes IFN-based treated patients.
530 A.L. Zignego et al. / Autoimmunity Reviews 16 (2017) 523–541hematological treatment schedule (375 mg/m2 in four consecutive
weekly infusions). Lower doses and/or shorter treatment have been
also reported, i.e., 1g every two weeks for two infusions or 250 mg/m2
in two administrations [81].
Since RTX is not active on B-cell progenitors, the effect is transitory
with variable duration of the clinical effect (from 3–4 months to more
than 12 months); long-term responses usually prevail. Before IFN-free
AVTs, repeated treatments [62,65,66,69] and maintenance regimens
were necessary, especially in patients with nephritis or severe abdomi-
nal vasculitis [66,68,69], because RTX has only a transitory effect and the
viral trigger (HCV) was still present. The relationship between etiologic
treatment and RTX is of interest. In the IFN era, most studies on RTX
have been performed on patients who had failed or were not eligible
for AVT, even if some authors suggested a combined RTX plus AVT in pa-
tients with severe manifestations (generally using RTX before AVT) [32,
66,84]. The effect of RTX treatment made eligible to IFN-based AVT
some previously excluded patients [78]. In two controlled clinical trials,
the combination of RTXwith AVT showed a synergistic effect [70,82,84],
being more effective in CV manifestations than AVT alone, particularly
when a kidney involvement was present [85,86]. The AVT after RTX
compared with RTX alone increased the relapse-free survival [87,88].
In most studies the combination was sequential, starting with RTX or
AVT depending on the condition of the patient while, in some others,
both therapies were administered concomitantly.
Data about combined RTX plus DAA-based therapy are still scarce
[41,61]. However, it is conceivable to figure out promising successes of
combination with IFN-free schedules. The exact place of RTX in the
field of CV has to bemore precisely defined.With the approval of recent
DAAs IFN-free combination,which proved very highly and rapidly effec-
tive on viremia, we will have to define in the next future the remaining
place of RTX. For example, as a first-line option for severe and life-
threatening conditions needing urgent intervention and a second-line
option for those maintaining significant symptoms after SVR.3.2. Lymphoma
In 1994, a high prevalence of HCV infection in Italian patients with
lymphoma was first reported in limited cohort of patients [89,90]. In
the last two decades, several evidence proved the association between
HCV infection and the occurrence of hematologic malignancies, mostly
B-cell non-Hodgkin's lymphoma (B-NHL) [91,92]. A clear gradient of
HCV-related lymphoma from North to South was also shown as for
HCV infection [1,93]. Dedicatedmeta-analyseswere able to confirm (al-
though with different degrees), an increased risk of lymphoma in HCV
infected subjects [92,94–97]. A confirmation derived also from the high-
ly significant reduction in the lymphoma risk found as a result of
sustained viral eradication [10,17]. This also suggested that AVT could
represent a preventive measure for the development of lymphoma.
The association did not involve a specific histopathological type of B-
NHL, although some of them appear more frequently related to HCV in-
fection. HCV was initially linked to indolent NHL, then the association
with aggressive subtypeswas also shown.Marginal Zone (MZL), Diffuse
Large B Cell (DLBCL) and Lymphoplasmacytic lymphomas
(Waldenstrom's macroglobulinemia, WM) were the most frequent re-
ported B-NHL in HCV infected patients [92,98,99].3.2.1. Etiologic treatment and its place with respect to non-viral treatment
Since the first report in 2002 by Hermine et al. in HCV-positive
splenic lymphoma with villous lymphocytes [100], a large series of evi-
dence demonstrated that IFN-based AVT is able to induce hematological
response alongwith virological clearance in patientswithHCV-associat-
ed low grade lymphomas (especially MZL) [101]. A recent meta-analy-
sis on 20 studies evaluated the efficacy of an IFN-based AVT in 254
patients with HCV-associated B-NHL [24]. Lymphoma response rate
was 73% in all patients and up to 83% in SVRs. A better lymphoma re-
sponse was shown in marginal zone compared to non-marginal zone
531A.L. Zignego et al. / Autoimmunity Reviews 16 (2017) 523–541lymphoma (81%vs.71%). Recent datawith IFN-free regimens inHCV-as-
sociated LPDs suggest their anti-lymphoma activity too [102].
On this basis, AVT should be considered the first-line approach in
HCV-associated low grade lymphomas if there is no immediate necessi-
ty of a conventional treatment (i.e., systemic symptoms, bulky disease
or symptomatic splenomegaly), irrespectively of liver damage (general-
lymild) [103], as also recommended by recently updated hematological
(ESMO [104] and NCCN [105]) and hepatology (EASL [106]) guidelines.
Among HCV-associated aggressive lymphomas, DLBCL is the most
frequent type [107]. An immediate conventional therapy is required,
being the immunochemotherapy scheme R-CHOP (rituximab, cyclo-
phosphamide, doxorubicin, vincristine, prednisone) the standard choice
[108]. The observation of a dissociation between HCV-RNA levels and
liver injury after immunochemotherapy, suggested that liver impair-
ment is not directly related to an enhanced HCV replication [109].
IFN-based AVT, when administered in combination with immuno-
chemotherapy significantly increased hematologic toxicity [110],
whereas, during the post-chemotherapy follow-up was associated to a
better outcome [111]. HCV eradication by IFN-free AVT after completion
of immunochemotherapy should also be recommendedwith the aim to
eliminate the lymphoma trigger and potentially reduce the risk of
lymphoma relapse [107,112]. Recently, it has been also reported that
treatment of HCV infection in transplant recipients improves both lym-
phoma and liver disease outcomes strongly suggesting the use of IFN-
free regimens following close monitoring for potential drug-drug inter-
actions [113]. Concurrent administration of DAAs and immuno-chemo-
therapy should be tested in prospective trials, although no particular
overlapping toxicities can be predicted. No specific recommendation is
possible for HCV-positive DLBCL relapsed or refractory to a first-line
treatment; however, high-dose chemotherapywith autologous support
seems feasible in this setting [114,115].
3.3. HCV-associated kidney diseases
The association between HCV and chronic kidney disease (CKD) is
undoubted. Several large surveys based on clinical databases suggested
a significant impact of HCV on prevalence and incidence of CKD [116,
117]. A large case-control study [118] showed a significant association
between HCV infection and membrano-proliferative glomerulonephri-
tis (MPGN). In addition, HCV positive subjects showed a significantly
higher prevalence of renal insufficiency (serum creatinine ≥ 1.5 mg/dl)
after adjusting for influencing variables [119–121].
As previously observed, cryoglobulinemic nephropathies
represent the most frequent conditions, with type I MPGN the
most common form. Membrano-proliferative glomerulonephritis
without cryoglobulinaemia, membranous nephropathy, and
mesangioproliferative glomerulonephritis are rare pictures. Occa-
sional observations of focal segmental glomerulosclerosis, fibrillary
or immunotactoid glomerulopathies, or thrombotic microangiopa-
thy have been also rarely reported [12]. MPGN can be diffuse or
focal (more or less than 50% of involved glomeruli), and it is charac-
terized by duplication of glomerular basement membrane (GBM),
GBM interposition by mesangial cells (especially monocytes), sub-
endothelial and mesangial deposition of immune reactants,
mesangial proliferation with leukocyte exudation, endoluminal hya-
line pseudo-thrombi (corresponding to cryoglobulin precipitates)
and, rarely, extra-capillary proliferation.
A correct therapeutic approach involves the early evaluation of ac-
tivity/severity of renal damage and its tendency to rapidly evolve,
with individual tailoring of treatment. As an example, in case of
cryoglobulinemic nephritis, the distinction between a diffuse or focal
MPGN and mesangial glomerulonephritis (the main glomerular pat-
terns of cyoglobulinemic nephritis) appears critical [122]. In fact, the
main histopathological changes characterizing MPGN may improve
with a strong immunomodulating treatment, including GCs and/or im-
munosuppressive agents and plasma exchange in escalation protocols.Consequently, these measures should be the first-line therapeutic ap-
proach, consideringAVT after improvement and stabilization of the con-
dition. GCs should be given only at the onset of the vasculitis process
and then rapidly tapered until discontinuation (see below). By contrast,
the use of AVT, especially DAA-based, should be recommended as first-
line approach in case of mesangial glomerulonephritis, where exuda-
tion, endo-capillary and extra-capillary proliferation, and endo-luminal
thrombi are almost invariably absent and the lesions are likely to be
self-limiting and spontaneously regressing. Significant poor prognostic
variables (i.e., age, male gender, creatinine and proteinuria at the time
of renal biopsy, number of clinical relapses, and poor blood pressure
control) should also be taken into account [122]. Kaplan–Meier survival
curves areworsened by creatinine value N 1.5mg/dL (133 μmol/L) at the
time of renal biopsy. Cardiovascular disease is the leading cause of death
(over 60 % of cases).
3.3.1. Etiologic treatment
The large majority of data about AVT have been derived from pa-
tients with CV. Several evidences justify the interest for HCV eradication
in the setting of kidney disease. These include, first, the consistent role
of the infection in conditioning the disease outcome (especially evident
in kidney transplanted patients), as well as the significantly higher
prevalence of HCV infection in nephropathic patients in comparison
with the general population. Additional data arise from studies showing
the positive effect of viral eradication on CKD and related mortality
rates. In a recent population-based cohort including patients with dia-
betes mellitus [5], the 8-year cumulative incidence of end stage renal
disease was significantly higher in HCV infected untreated than in the
AVT treated and uninfected cohorts (p b 0.001). In the past years CV pa-
tients showed greater renal response rates when treated with a combi-
nation of RTX and PegIFN plus RBV compared with PegIFN and RBV
alone [85,86]. The only availability of IFN-based AVT have been a limita-
tion to the etiologic approach. However, the Kidney Disease Improving
Global Outcomes (KDIGO) Group recommended in 2008 to treat pa-
tients with flares of CV MPGN with AVT, even if IFN-based; RBV dosage
should be closely monitored due to the risk of anemia [123]. No doubt
such recommendations are today obsolete. Recently, IFN-free AVTs,
due to their good tolerance profile (despite some concerns regarding
pharmacokinetics and safety in patients with severe renal failure)
[124], will probably positively change the epidemiology of HCV-associ-
ated nephropathy. Sise et al., observed on a small cohort of 7 patients
with CV and glomerulonephritis treated with IFN-free AVT that a
SVR12 was correlated to an improvement in serum creatinine and a re-
duction in proteinuria [43]. In other recent observations the improve-
ment of kidney disease in virological responders was progressively
more evident from the inhibition of viral replication to 12 or 24 weeks
after therapy [17,44,46].
3.3.2. Non-etiologic treatment
Immunosuppression is still regarded as the first-line intervention in
CV if renal involvement is severe/rapidly progressive. In these cases,
AVT is usually insufficient to rapidly control renal disease and has also
been shown to be detrimental in case of IFN and/or RBV. The conven-
tional high-dose GCS, plasmapheresis, and, in more severe cases, cyto-
toxic therapy, have been commonly administered in patients with
cryoglobulinemic nephritis [125]. Patients usually require multiple
courses because of recurrent flares even after a prolonged remission.
The combination of CTX (1.5–2 mg/kg/day given orally for 3 months,
or 0.5–1 g administered intravenously every 2–4 weeks) in association
with oral GCs (0.5–1 mg/kg/day for 1 month with subsequent tapering
by 2.5–5 mg/week), often preceded by 3 pulses of 10–15 mg/kg meth-
ylprednisolone, represents a common therapy in the severe forms of
cryoglobulinemic nephritis. The less toxic mycophenolate mofetil,
given for 6 months, can be an alternative option to CTX. Plasma ex-
change, especially double-filtration plasmapheresis, continues to be
successfully used in escalation protocols for rapidly progressive
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tion with GCs and also with AVT in several studies. Detailed renal out-
comes can be achieved on over 200 patients; renal response
(complete plus partial) was 70–90%. Glomerulonephritis usually im-
proves within 3 months; complete healing takes longer. No substantial
adverse effects of RTX on HCV viremia were observed. However, a flare
of CV has been reported in patients with high CG level receiving high
doses RTX (1000 mg), suggesting that in such patients the protocol
should start with plasmapheresis and then use the classical schedule
(375 mg/m2 per infusion) [126]. In a study on a large cohort of biop-
sy-proven severe cryoglobulinemic nephritis followed for 6 years after
the administration of the 4 + 2 × 375 mg/m2 protocol, the survival
rate was 75% at 6 years and the probability of remaining symptom-
free for 10 years was of about 60% [127].
3.4. Neuropsychiatric disorders and health-related quality of life (HRQOL)
3.4.1. Neuropsychiatric disorders
HCV is associatedwith various neuropsychiatric disorders [128]. The
prevalence of depression is higher in HCV infected patients than in the
general population (59% versus 21%) [129]. Approximately 60% of HCV
infected patients suffer of sleep disorders [130], fatigue (prevalence:
50–67%) [131] and mood disorders that, in turn, negatively and inde-
pendently affect the quality of life [132,133]. Cognitive impairment
was also described [134,135]. Thesemorbidities did not completely cor-
relate with liver disease severity, suggesting a direct association with
HCV [136,137]. It has been hypothesized that the virus enters the Cen-
tral Nervous System (CNS) infecting CD68+ peripheral cells, microglia
precursors [138]. Therefore, viral proteins could exert a neurotoxic ef-
fect [139,140]. The increased expression of cytokines, such as TNF-
alpha and IL-8, could also play a role at local and systemic level [141,
142]. Furthermore, HCV may directly affect the serotonergic and dopa-
minergic neurotransmission with resultant depressive symptoms
[143]. Rarely, neuropsychiatricmanifestations are secondary to HCV-in-
duced CV with abnormal brain MRI [144].
3.4.2. Health related quality of life (HRQoL)
Naive HCV-positive patients are characterized by poor HRQoL com-
pared to the general population [145–147]. Based on the Short Form
36 (SF-36) Health Survey questionnaire, they consistently show deficits
in several domains, particularly those involving physical role, general
health and vitality [148–150]. In turn, poor HRQoL can lead to difficul-
ties with interpersonal relations, decreased feelings of self-value and
utility, and depression, with a decreased ability both at work and at
home, and obvious cost implications.
3.4.3. Etiologic treatment
The relationship between mood disorders and IFN-based AVT has
been widely discussed. IFN side-effects increased with higher doses
and longer therapies [151]; the onset of depression has been observed
in 30%–70% of treated patients [152,153]. IFN was also associated with
sleep disturbances, anxiety, cognitive disorders (up to 50%), while ma-
niac and psychotic symptomswere less frequent (3% of patients). Irrita-
bility is also an important side-effect, involving approximately 75% of
patients during therapy.
The HRQoL records during IFN and RBV therapy are usually low and
the average scores of the SF-36 worsen rapidly, in particular, in the
physical role, emotional role, vitality and social functioning [154]. Con-
sequently, before to initiate an IFN-based treatment, a psychiatric
counseling, should be recommended [151]. In some cases, the manage-
ment of symptoms requires a therapy including pharmacological sup-
port with antidepressants (particularly selective serotonin reuptake
inhibitors) or with benzodiazepines [155]. The possible co-morbidity
with substance abuse limits the use of these drugs, for the risk of re-
bound effect, tolerance and dependence. In most instances theneuropsychiatric symptoms are resolved after IFN discontinuation.
After SVR, theHRQoL scores improve compared to baseline values [156].
The effect on HRQoL of IFN-free treatment has been studied by
Younossi and colleagues in patients treatedwith sofosbuvir-based com-
binations with or without RBV [154,157,158]. Compared to placebo,
these treatments were not associated with HRQoL impairment and the
SVR correlated with HRQoL improvement [154]. Nevertheless, the pres-
ence of RBV still seems to poorly influence HRQoL, partly due to hemo-
globin reduction: patient-reported outcomes (PRO's) are higher in RBV-
free regimens [158].
In conclusion, compared to IFN-based, IFN-free AVTs, cause minimal
reduction in PROs during therapy and improvement of vitality and fa-
tigue at SVR12 [158]. Although few specific drug-drug interactions
have been described between psychotropic molecules and DAAs (i.e.
between Ritonavir and Carbamazepine, Nefazodone and Triazolam)
[159] a cautious approach is needed since pharmacokinetic interactions
can induce increase or reduction of one or both drugs, with toxicity or
under-dosing risks.
3.5. Porphyria cutanea tarda (PCT)
PCT is characterized by low activity of uroporphyrinogen decarbox-
ylase (URO-D) involved in heme synthesis. It can be classified as familial
or sporadic. In the acquired, sporadic form (type I PCT) a 50% deficient
activity of URO-D in the liver leads to an overt manifestation; this can
be the consequence of a trigger such as HCV, alcohol and liver toxins
[160–162]. Iron overload (hepatic siderosis) is a critical pathogenetic
event, disrupting the enzymatic activity of URO-D by inducing the for-
mation of an intracellular inhibitor [163]. The relationship with HCV in-
fection is supported by epidemiological associations, especially in some
geographical areas [164]. However, the absence of altered porphyrin
metabolism in HCV-positive patients without PCT, argues against a di-
rect role of HCV. PCT manifestations include typical cutaneous lesions
in sun-exposed areas, photosensitivity, skin fragility, facial
hypertrichosis and late-stage sclerodermoid plaques.
3.5.1. Etiologic treatment
The indirect role played by HCV infection and the sensitivity to the
iron deposits due to thehemolytic effect of RBV,may explain the contro-
versial results reported with IFN/RBV AVT. On one hand, an effective
AVT may potentially improve clinical and laboratory manifestations of
PCT, especially when preceded by therapeutic phlebotomy [162]. On
the other hand, a worsening and a new-onset PCT have been reported
in some cases [165], possibly due to the RBV-induced hemolytic anemia,
further increasing liver iron excess. It is expected that the management
of this condition could benefit from a viral eradication with both IFN-
and RBV-free regimens, but no data are available today. It is also con-
ceivable that DAAs already known to cause photosensitivity have to be
avoided.
3.5.2. Non-etiologic treatment
The standard of care for PCT includes photo-protection, anti-malarial
drugs (chloroquine) and phlebotomy, the latter to reduce hepatic iron
stores [163].
3.6. Lichen planus
Lichen planus (LP) is an inflammatory disorder involving the skin
and the oro-genital mucous membranes. Oral LP is the most studied
phenotype in the setting of HCV infection [166]. The association with
HCV has been widely described [167] and it has been suggested that
HCV-LP is the result of a T-cell mediated autoimmune reaction [168,
169]. Conflicting datamay depend on geographical and/ormethodolog-
ical factors, with genetics (HLA-DR-associations), age and IFN-based
AVT also playing a role [163].
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IFN-based AVT should be avoided. In fact, type-1 IFNs are a major
driver of lichenoid inflammation [170] and IFN-based AVT may nega-
tively influence established LP or induce the onset of lichenoid lesions.
This increases the interest for studies on IFN-free AVT, although no
data are available at present.
3.6.2. Non-etiologic treatment
Treatment of LP is based on a step-wise approach with the use of
topical and/or systemic immune-modulating agents, tailored on
disease's characteristics [171]. Systemic treatment is indicated in se-
vere/advanced disease, and includes retinoids (acitretin), GCs, metho-
trexate, and cyclosporine [172]. In HCV-positive LP it should be
performed considering the severity of liver disease: a strict follow-up
of the main liver function tests (LFTs) should be performed as well as
an accurate evaluation of the possible drug-drug interactions between
DAAs and non-etiologic drugs (i.e., cyclosporine).
3.7. HCV-associated endocrine disorders
The main endocrine HCV-EHDs are represented by thyroid diseases
and type 2 diabetes mellitus (T2DM) [19,127]. Gonadal dysfunctions
are reported in male HCV-infected individuals [19], but data on specific
therapies are lacking.
3.7.1. Thyroid disorders
Autoimmune thyroid diseases are among the most frequent endo-
crine disorders in HCV infected patients [173]. They result from a dys-
regulation of the immune system leading to T cell-mediated organ-
specific autoimmunity. In 80–85% of cases, circulating thyroid autoanti-
bodies are detected; thyroid ultrasonography and cytology can help in
the diagnosis. A thyroid dysfunction (mainly hypothyroidism) is pres-
ent in about 30% of patients [127]. In a recent meta-analysis, the preva-
lence of anti-thyroglobulin antibody (AbTG), anti-thyroid peroxidase
antibody (AbTPO), anti-thyroid microsomal antibody (ATMA) and hy-
pothyroidism were higher in HCV positive patients than in controls
[174]. An even higher prevalence of thyroid dysfunction was observed
in HCV-CV patients [175,176].
A higher prevalence of papillary thyroid cancer has been found in
chronically HCV-infected patients, particularly in those with autoim-
mune thyroid diseases [173]. In a recentwide cohort study, anti-HCV se-
ropositivity was associated with multivariate-adjusted hazard ratio for
thyroid cancer [6].
3.7.1.1. Etiologic treatment. IFN-α therapy is a well-known risk for the
development of autoimmune thyroid diseases and thyroid dysfunctions
[177]. Thyroid disease developed in up to 25–30% of HCV patients dur-
ing Peg-IFN/RBV treatment, and about half of these patients need thy-
roid treatment [178]. Most patients with IFN-α-induced
hyperthyroidismpresentHashitomoto disease andhave a transitory hy-
perthyroidism, while a minority of them develop Graves' disease. In pa-
tients with long-term hyperthyroidism and Graves' disease, radioiodine
therapy was effective and well-tolerated [179].
A recent study retrospectively analyzed data from Graves' disease
patients with or without HCV infection treated with IFN-α or
methimazole (MMI), respectively. Results suggested a more favorable
course of Graves' disease inHCVpatients treatedwith IFN-α, than in un-
infected patients [180].
Assessment of thyroid-stimulating hormone (TSH) and thyroid au-
toantibodies at baseline and closemonitoring of thyroid function during
Peg-IFN/RBV therapy are necessary for early detection andmanagement
of IFN-induced thyroid disease [181].
High values of the circulating prototype Th1 chemokine (C-X-C
motif) ligand 10 (CXCL10), are present in HCV CHC and CV patients
with autoimmune thyroid diseases [182]. However, lower pretreatment
serum CXCL10 levels were associated with thyroid disease, and thyroiddisease prevalence increases in HCV female patients and patients who
are positive for AbTPO at baseline, treated with PEG-IFNα-2a/RBV
[183]. In another study, thyroid disease with high TSH levels has been
shown to be associated with good response to Peg-IFN/RBV [184].
Currently, scarce data exist about IFN-free AVT. The possibility of in-
teractions of levo-thyroxine (L-T4) (the common treatment for HCV au-
toimmune thyroid diseases) [185] with DAAs suggest an accurate
tailoring of treatment schedules [186].3.7.1.2. Non-etiologic treatment. Treatment of thyroid disease (hypothy-
roidism/hyperthyroidism) or thyroid cancer should be performedwhen
needed, according to the current specific guidelines [187].3.7.2. Type 2 diabetes mellitus
Epidemiological data support the association between HCV infection
and T2DM [19,188]. In a review of 102 studies, diabetes was one of the
most common HCV-EHM (15% of patients) [189] with important impli-
cations for outcome, prevention and treatment. It was shown that
T2DM, with or without insulin resistance (IR), reduces responsiveness
to IFN-based AVT [190,191] and was associated with higher risk of de-
veloping cirrhosis and hepatocellular carcinoma (HCC), even after
viral eradication [192,193].
HCV may induce IR through multiple mechanisms [194]. In turn, IR
plays a crucial role in fibrosis progression, and has a negative impact
on AVT responses [195]. Obesity and physical inactivity also cause
hyperinsulinemia, and accelerate HCV-induced damage [196]. HCV-in-
duced IR can also lead to arterial hypertension, hyperuricemia, and ath-
erosclerosis, resulting in increased cardiovascular mortality. The
interaction of T2DM with CHC and “non-alcoholic fatty liver disease”
(NAFLD) may result in a “vicious circle”, that can lead to an increased
risk of all-cause mortality and liver-related and cardiovascular compli-
cations [197,198]. In turn, HCV infection in patients with T2DM may
also increase the proportion of DM-related kidney complications [199].3.7.2.1. Etiologic treatment.Most available data are concerning IFN-based
AVT. Clinical trials reported improvement of glucose metabolism [200]
and reduction in the T2DM incidence after HCV eradication [201].
Concerning DAAs, a case report showed improved glycemic control
after a successful sofosbuvir-based regimen in a patient with poorly
controlled T2DM [202], while other analyses showed amarginal impact
of IFN-free regimens on hemoglobin A1c [203]. T2DM was also a nega-
tive predictor of patient-reported outcomes [204]. Further studies are
needed to correctly evaluate the AVT influence on the long-term course
of T2DM.3.7.2.2. Non-etiologic treatment. HCV-T2DM requires [205] various mea-
sures including: lifestyle changes, regular diabetes screening, analysis of
other risk factors accelerating both CHC and DM, such as obesity, dyslip-
idemia, and alcohol consumption. Early identification and treatment of
IR or T2DM reduce liver disease progression [206], incidence of HCC,
transplant-related morbidity and mortality, and improve the AVT re-
sponse [191,207], minimizing side effects [200].
Therapeutic options in HCV-T2DM include diet changes, anti-diabet-
ic drugs, statins. It is not clear whether the best approach is a peroxi-
some proliferator-activated receptor (PPAR) agonist or a biguanide
such asmetformin [208–210]. Prospective, randomized controlled trials
showed increased SVR usingmetformin in HCV patients with IR receiv-
ing AVT [211]. Different analyses that evaluated metformin use in these
patients showed a significant reduction of HCC, liver-related death, and
liver transplant with an increased survival rate [211]. Concerning
statins, the inhibition of HCV replication was shown in vitro [128], but
not in vivo [212,213].
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The frequent association between sicca syndrome andHCV infection
has been shown by both experimental and epidemiological studies
[160,214,215]. Sicca syndrome related symptoms have been reported
in 20% to 30% of HCV patients, whereas less than 5% of patients with a
defined Sjögren's syndrome are HCV-positive [216]. Although low titers
of antinuclear antibodies and RF are common in patients with HCV-re-
lated sicca syndrome, the presence of primary Sjögren's syndrome relat-
ed autoantibodies (anti-SSA/SSB) is uncommon.
Similarities exist between HCV-related sicca syndrome and “true”
primary Sjögren's syndrome. However, HCV-positive sicca syndrome
patients are older and more likely to have photosensitivity and CV
than patients with primary Sjögren's syndrome [217]. Patients with
CV may develop a mild sicca syndrome in the absence of typical histo-
pathological and/or serological alterations. In some cases the differential
diagnosis between primary Sjögren's syndrome and CVmay be very dif-
ficult, mainly in patients with overt sicca syndrome, cryoglobulinemia,
and HCV infection [218].
3.8.1. Etiologic treatment
IFN-based AVT generally has scarce clinical efficacy, probably be-
cause in many cases, the onset of symptoms is a consequence of gland
destruction. There is no available data with IFN free DAAs.
3.8.2. Non-etiologic therapy
Besides topical treatments that may partially improve HRQoL, there
is no specific systemic treatment for HCV-associated sicca syndrome
[219].
3.9. Arthritis
Arthralgia is common in HCV-infected patients [220] while arthritis
is rare (4%–5%) [221,222]. Two different subsets of HCV-related arthritis
have been identified in some studies on limited groups: the more com-
mon symmetrical polyarthritis and the intermittentmono-oligoarthritis
[223–226]. The symmetrical polyarthritis subset shares several aspects
with rheumatoid arthritis (RA): symmetrical involvement of wrists
and hands; positive RF in more than 50% of patients, and increased in-
flammation markers. However, the course of HCV related symmetrical
polyarthritis is less aggressive when compared with RA, typically non-
deforming and not associated with articular bone erosions; rheumatoid
nodules were never reported [227,228]. Anti-CCP antibodies can be
helpful in the differential diagnosis between HCV related symmetrical
polyarthritis and RA because they are rarely detected in the former
and almost constant in the latter [229,230]. The intermittent mono-
oligoarthritis subset typically involves the medium and large joints of
the lower limbs, mainly the ankles [227,228]. Its course is usually
acute, with frequent relapses. The intermittentmono-oligoarthritis sub-
set is closely related to cutaneous and laboratory manifestations of CV.
Intermittentmono-oligoarthritis flares frequently occur simultaneously
to skin flares of CV.
3.9.1. Etiologic treatment
It has been suggested that, once the diagnosis of HCV-associated ar-
thritis is made, AVT can be taken into account. PegIFN plus RBV AVT has
been successfully used [19,225,231], but it can promote the worsening
of arthritis in others [232]. Therefore, it is conceivable that IFN-free reg-
imens will be more useful.
3.9.2. Non-etiologic treatment
Anti-TNF agents are safe in patients with concomitant HCV infection
and classical RA [233], but their use appears generally excessive. Thera-
peutic approaches to HCV-related arthritis remains largely empirical,
because few studies have been published. Usually, HCV-related arthritis
patients may respond to low doses GCs and hydroxychloroquine.Concernsmay be raised regarding the use of immunosuppressive or po-
tentially hepatotoxic drugs, in particularmethotrexate and leflunomide,
often not necessary or contraindicated. On the contrary, RTX may be
successfully employed,mainly in patientswithmore aggressive disease,
and may represent the first-choice treatment in patients with arthritis
in the setting of CV [234].
3.10. Miscellanea
For other HCV-EHMs, data about the effect of viral eradication
(representing the most important argument in favor of a true
etiopathogenetic association) are, at present, too scarce or absent.
Some of these can represent either EHMs or side-effects of AVT or con-
sequences of advanced liver damage, making frequently difficult their
exact attribution. These latter include pruritus, psoriasis and other
skin disorders. Other cases, like urticaria, have been only suspected to
be associated with HCV, due to the existence of both limited and discor-
dant data.
4. Discussion
We recently formed an International Study Group of Extrahepatic
Manifestations related to HCV (ISG-EHCV)with the aim to provide a ho-
mogeneous clinico-diagnostic [19] and therapeutic approach toHCVpa-
tients presenting with HCV-EHMs through the development of a
multidisciplinary international network of experts.
This paper summarizes recommendations about a new hot and
discussed topic in the managing of HCV infection: the therapeutic ap-
proach to various extrahepatic diseases more or less directly linked to
this infection. HCV-EHMs have been shown to be responsible for signif-
icantly higher mortality/morbidity rates when compared with non-in-
fected (or no more infected) subjects [6], with important
consequences in terms of social costs.
The present recommendations are based only on scientific criteria
and do not take into account the debated issue related to the cost/ben-
efit ratio, which is also a concern, especially in some regions of the
world.
In eachHCV-EHM, the actual pathogenic role played by the viruswas
evaluated in order to better understand the opportunity and urgency to
use AVT. In turn, the possibility to completely eradicate the infection,
appears crucial to better evaluate such a role (“ex adiuvantibus criteri-
um”). For disorders, like the HCV-related LPDs, the effect of viral eradi-
cation represents the stronger proof of the etiopathogenetic
involvement of HCV. In this light, however, the former IFN-based etio-
logic therapy frequently provided an uncertain “ex adiuvantibus” pic-
ture, due to indirect immunomodulatory effects of IFN, especially in
studies with a short follow-up. The availability of drugs directly acting
on the virus in IFN-free combinations led to minimize or abolish (in
both IFN- and RBV-free regimens) such immunomodulatory effects.
Furthermore, their safety promises to allow the HCV eradication also
in patients previously intolerant with severe HCV-EHMs. On the other
hand, it is conceivable that, in some cases, the positive effects on HCV-
EHMs (improvement or resolution) at the end of treatment and in the
early post treatment period, will be less evident compared to IFN-
based AVT. Available, although limited data, obtained in HCV LPDs like
CV andNHL [46] seem to be in agreementwith this hypothesis, suggest-
ing the opportunity for a longer follow-up. A long-term post-treatment
follow-up appears of interest also in other HCV- EHMs, in order to eval-
uate the real impact of DAA-based therapy.
Another confirmation arises from the observation of a paradoxical
improvement of some HCV-EHMs despite of HCV persistence (virologic
non-response), observed after IFN-based regimens and usually tran-
sient [17]. The availability of drugs without immune-modulatory prop-
erties, makes also easier the decision to treat patients with autoimmune
disorders and uncertain viral etiopathogenesis, thus at risk ofworsening
after an IFN-based therapy. The availability of IFN-free AVT support the
535A.L. Zignego et al. / Autoimmunity Reviews 16 (2017) 523–541recommendation to eradicate, as soon as possible, a virus known to
strongly sustain B-cell activation and with lymphomagenetic potential.
In other words, IFN-free AVT should be a priority in HCV-positive auto-
immune and/or lymphoproliferative disorders, even if the liver damage
is not severe.
The urgent need of clear and easy-to-use therapeutic guidelines,
comes from this specific aspect in managing a patient with EHMs. The
hepatologist has to be advised that a counseling with a specialist may
be not sufficient, because both physicians should recognize a new sys-
temic pathological entity generated by the infection, the so-called
HCV-disease [19]. In more details, the therapeutic approach could not
be referred to specialist guidelines for each specific manifestation/
symptom, but should take into account the strong impact on all the as-
pects of HCV infection. This should happen not only when the probabil-
ity is high that HCV is the causal agent of an EHM (as it is for HCV-CV),
but also when the virus is only a trigger (as for HCV-PCT).
The exchange of information between different specialists has to aim
at evaluating the pros and contras of different interventions and their
timelines. An exemplary case is represented by situations requiring a
non-etiologic priority approach (i.e. rapidly evolving HCV-EHMs or,
conversely, in absence of national health care reimbursement as pres-
ently in some countries. Another example is given by difficult-to-treat
cases for patient's characteristics (i.e. advanced cirrhosis in an experi-
enced patient previously not responsive to AVT) and/or for the virus
(i.e. HCV genotype 3). Usually, in these conditions, RBV is indicated to
increase the chances of viral eradication, but it is contraindicated or
should be used cautiously for some EHMs (i.e. in presence of ischemic
damage, significant renal damage, PCT).Table 5
Take-home messages
Antiviral (etiologic) treatment of HCV-EHMs
• IFN-free, DAA-based antiviral therapy should be considered a first line
therapeutic measure for HCV-EHMs that does not need urgent/life threatening
measures
• All patients with HCV-EHMs without short life expectancy due to non
HCV-related comorbidities should be considered for treatment
•When universal treatment may not be scaled up, HCV-EHMs should be
considered a prioritization criterion
• The first target of etiologic therapy is the HCV eradication and consequent
HCV-EHM improvement
• The degree of HCV-EHM clinical improvement depends on the degree of
reversibility of the HCV-induced damage and/or the underlying pathogenic
process : early viral eradication is recommended
• IFN-free DAA treatment of HCV-EHMs, should follow general criteria
standardized for the treatment of HCV infection, accurately taking into account the
HCV-EHMs characteristics
• Both IFN- and RBV-free DAA therapy should be preferred in patients with kidney
disease, PCT, ischemic tissue lesions (i.e., skin ulcers, ischemic heart disease),
anemia (i.e., in LPDs)
• Therapy of kidney disease imply a careful approach, including accurate evaluation
of the kidney damage and choice of DAA treatment and follow-up schedule
• Using IFN-free DAA therapy, the possible “rebound effect” of abrupt withdrawn of
non-etiologic therapy should not be interpreted as DAAs side effect
Non antiviral (non etiologic) treatment of HCV-EHMs
• Non-etiologic therapy is the first line treatment in case of HCV-EHMs needing
urgent/life threatening measures, but should be useful also in less severe cases
before, during or after antiviral therapy in patients with persistent disease
• The combination of IFN-free DAA and non-etiologic therapy can be allowed,
especially in severe cases
• Persistence after antiviral therapy of immunological/laboratory abnormalities
(i.e., cryoglobulinemia) in the absence of any clinically evident disease, does not
justify therapy
• The choice of non-etiologic therapy should always take into account the degree of
HCV-related liver damage and, in case of DAAs co-administration, the possible
drug-drug interactions
• In clinically moderate-severe autoimmune/lymphoproliferative HCV-EHMs
(especially cryoglobulinemic vasculitis) with failure or contraindication to
antiviral treatment, Rituximab should be considered a first line therapeutic
measure. Combined treatment can be indicated.Non etiologic therapies also need a close collaboration between spe-
cialists of different medical areas: i.e. to manage patients with co-mor-
bidities requiring a chronic administration of drugs potentially
interacting with some DAAs. This means that it is important to agree
on tailoring both the AVT and the other therapies possibly rescheduling
one and/or making appropriate changes with non-interfering alterna-
tive drugs. Dedicated websites could support and help the health care
providers in this kind of decision.
The critical point is therefore a wider and multidisciplinary spread-
ing of the knowledge about HCV-EHMs, in order to provide a more con-
scious and aware approach. The present recommendations are designed
to address this need. They mean to briefly recall to non-specialists, the
essential features of the different manifestations of the HCV disease in
order to provide the best intervention in terms of etiologic and/or
non-etiologic (pathogenetic-symptomatic) treatments.. This would be
the necessary basis for future modifications according to available new
data. A Delphi survey provided by the same expert group recently
scored the principal statements (Ramos-Casals M et al. J. Hepatology,
in press).
Overall, the main take home messages we can highlight from the
available data are briefly summarized in Table 5.
In conclusion, although the hope for a definitive cure for the HCV
EHMs seems to be closer than ever, the complexity of these patients in
whom different etiopathogenic scenarios are coexisting (autoimmune,
metabolic, neoplastic) anticipate a more difficult therapeutic scenario
than that is now reported in the standard HCV infected patients'
population.
In other words, with this work we would like to provide patients,
health care practitioners and specialists of the referral centers proper in-
formation on the structured and comprehensive management of pa-
tients with a complex pathological entity, the HCV disease.
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